In this context, a recent study using a 4T1 breast cancer model has shown that intratumoral injection of a GPR81 inhibitor along with an MCT inhibitor resulted in a significant reduction in tumor burden in mice (38). The gene discussed is SLC16A1; the disease is neoplasm.